Addressing a broad range of acute and chronic diseases
Our Shielded Living TherapeuticsTM platform combines advanced cell differentiation and engineering techniques with innovations in biocompatible materials, potentially enabling our products to produce a wide range of functions or therapeutics molecules that may be missing or deficient in the body, including proteins, enzymes or other therapeutic molecules.
Our pipeline primarily spans a range of endocrine and lysosomal diseases, with the current focus on diabetes. Our product candidates are designed to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or chronic suppression of the patient’s immune system.
ProgramProg | Cell Product/TypeProd/Type | DiscoveryDisc | Lead OptimizationLead | IND EnablingIND | Phase 1/2Ph 1/2 | |
|---|---|---|---|---|---|---|
Lead Program | ||||||
SIG-002 - Type 1 Diabetes  | Human Insulin I | SIG-002 - Type 1 Diabetes Human Insulin I | ||||
Lysosomal Diseases | ||||||
SIG-205 - CNS MPS-1 | BBB - Human IDUA E | SIG-205 - CNS MPS-1 BBB - Human IDUA E | ||||
SIG-207 - Fabry | Human GLA E | SIG-207 - Fabry Human GLA E | ||||
SIG-218 - CNS MPS-2 | BBB - Human IDS E | SIG-218 - CNS MPS-2 BBB - Human IDS E | ||||
SIG-220 - MPS-6 | Human ARSB E | SIG-220 - MPS-6 Human ARSB E | ||||
Liver Diseases | ||||||
SIG-XXX - Undisclosed | ApoL-IL10 E | SIG-XXX - Undisclosed ApoL-IL10 E | ||||
SIG-XXX - Undisclosed | Human Hepatocyte I | SIG-XXX - Undisclosed Human Hepatocyte I | ||||